Literature DB >> 22003361

Role of macrophages in uveal melanoma.

Martina C Herwig1, Hans E Grossniklaus.   

Abstract

Tumor-associated macrophages have been related to a worse prognosis for survival in several tumors, among them uveal melanoma. In particular for proangiogenic and anti-inflammatory M2-type macrophages, a contributory role to tumor growth has been described. This study demonstrated that most tumor-associated macrophages in uveal melanoma exhibited the M2-phenotype. Tumors with monosomy 3 that have an unfavorable prognosis exhibited significantly more M2-type macrophages than tumors with disomy of chromosome 3. These findings point to a possible pathophysiologic mechanism that links an inflammatory phenotype in uveal melanoma with structural chromosomal abnormalities such as monosomy 3.

Entities:  

Year:  2011        PMID: 22003361      PMCID: PMC3190177          DOI: 10.1586/eop.11.45

Source DB:  PubMed          Journal:  Expert Rev Ophthalmol        ISSN: 1746-9899


  20 in total

1.  Ocular immune privilege: a review.

Authors: 
Journal:  Clin Eye Vis Care       Date:  2000-12

Review 2.  Ocular immune privilege and the Faustian dilemma. The Proctor lecture.

Authors:  J W Streilein
Journal:  Invest Ophthalmol Vis Sci       Date:  1996-09       Impact factor: 4.799

Review 3.  Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes.

Authors:  Alberto Mantovani; Silvano Sozzani; Massimo Locati; Paola Allavena; Antonio Sica
Journal:  Trends Immunol       Date:  2002-11       Impact factor: 16.687

4.  Detection of M2-macrophages in uveal melanoma and relation with survival.

Authors:  Inge H G Bronkhorst; Long V Ly; Ekaterina S Jordanova; Johannes Vrolijk; Mieke Versluis; Gregorius P M Luyten; Martine J Jager
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-02-03       Impact factor: 4.799

Review 5.  Macrophages, innate immunity and cancer: balance, tolerance, and diversity.

Authors:  Alberto Mantovani; Antonio Sica
Journal:  Curr Opin Immunol       Date:  2010-02-09       Impact factor: 7.486

Review 6.  Altered macrophage differentiation and immune dysfunction in tumor development.

Authors:  Antonio Sica; Vincenzo Bronte
Journal:  J Clin Invest       Date:  2007-05       Impact factor: 14.808

7.  Significance of M2-polarized tumor-associated macrophage in pancreatic cancer.

Authors:  Hiroshi Kurahara; Hiroyuki Shinchi; Yuko Mataki; Kousei Maemura; Hidetoshi Noma; Fumitake Kubo; Masahiko Sakoda; Shinichi Ueno; Shoji Natsugoe; Sonshin Takao
Journal:  J Surg Res       Date:  2009-06-16       Impact factor: 2.192

8.  Monosomy of chromosome 3 and an inflammatory phenotype occur together in uveal melanoma.

Authors:  Willem Maat; Long V Ly; Ekaterina S Jordanova; Didi de Wolff-Rouendaal; Nicoline E Schalij-Delfos; Martine J Jager
Journal:  Invest Ophthalmol Vis Sci       Date:  2008-02       Impact factor: 4.799

9.  Macrophage markers in serum and tumor have prognostic impact in American Joint Committee on Cancer stage I/II melanoma.

Authors:  Trine O Jensen; Henrik Schmidt; Holger Jon Møller; Morten Høyer; Maciej Bogdan Maniecki; Pia Sjoegren; Ib Jarle Christensen; Torben Steiniche
Journal:  J Clin Oncol       Date:  2009-06-15       Impact factor: 44.544

10.  Ovarian cancer cells polarize macrophages toward a tumor-associated phenotype.

Authors:  Thorsten Hagemann; Julia Wilson; Frances Burke; Hagen Kulbe; Ninfeng Fiona Li; Annette Plüddemann; Kellie Charles; Siamon Gordon; Frances R Balkwill
Journal:  J Immunol       Date:  2006-04-15       Impact factor: 5.422

View more
  3 in total

Review 1.  Molecular pathology of uveal melanoma.

Authors:  S E Coupland; S L Lake; M Zeschnigk; B E Damato
Journal:  Eye (Lond)       Date:  2012-12-07       Impact factor: 3.775

2.  Progression of ocular melanoma metastasis to the liver: the 2012 Zimmerman lecture.

Authors:  Hans E Grossniklaus
Journal:  JAMA Ophthalmol       Date:  2013-04       Impact factor: 7.389

Review 3.  Uveal melanoma: estimating prognosis.

Authors:  Swathi Kaliki; Carol L Shields; Jerry A Shields
Journal:  Indian J Ophthalmol       Date:  2015-02       Impact factor: 1.848

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.